C21 H23 N3 O2
2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-
Panobinostat is in Phase 1/2 development as a latency-reversing agent for HIV treatment.
(Compound details obtained from ChemIDplus Advanced,1 Treatment Action Group website,2 Farydak Full Prescribing Information,3 Journal of Biomedicine and Biotechnology article,4 and ClinicalTrials.gov5)
What is panobinostat?
Panobinostat (brand name: Farydak) is a drug that has been approved by the U.S.(FDA) for the treatment of a certain type of cancer.3 It is also being studied as an as part of a strategy to cure HIV . As an investigational HIV therapy, panobinostat belongs to a group of drugs called .2,5,6
How do latency-reversing agents work?
Currently, there is no cure for HIV infection. One of the main obstacles to curing HIV infection is that thecan remain hidden and inactive (latent) inside certain cells of the (such as resting CD4 cells) for many months or even years. The cells where latent HIV hides are known as the . Because HIV in this latent state is inactive, the immune system cannot detect the virus, and the (ARV) drugs that are used to treat HIV have no effect on it.7–9
Latency-reversing agents work by drawing HIV out of its latent state within resting CD4 cells. Once the latent HIV is reactivated, the CD4 cells that harbor the virus are more likely to be recognized and killed by the body’s immune system or may be killed by certain HIV therapies, such as those that can enhance the body’s What is a Latent HIV Reservoir? fact sheet.to HIV. Researchers hope that the combined use of panobinostat and other HIV-fighting strategies, including ongoing (ART), may fully eliminate HIV from the body.7–9 To learn more, see the HIVinfo
Which clinical trials are studying panobinostat?
Study Names: CLEAR; NCT01680094
Status: This study has been completed.
Purpose: The purpose of this study was to evaluate the safety and effectiveness of panobinostat in reactivating latent HIV within resting CD4 cells.6
Study Names: ACTIVATE; NCT02471430
Status: This study is currently recruiting participants.
Location: United States
Purpose: The purpose of this study is to evaluate whether a combination of the HDAC inhibitor panobinostat and the immunomodulator peginterferon alfa-2a (brand name: Pegasys) can reduce the latent HIV reservoir.5
For more details on the studies listed above, see the Health Professional version of this drug summary.
What side effects might panobinostat cause?
One goal of HIV research is to identify new drugs that have fewer side effects. In the CLEAR study (NCT01680094) discussed under the previous question, all panobinostat-related side effects were mild in severity. The most common side effect related to panobinostat was fatigue. Some minor changes in counts and counts were seen, but these changes were temporary.10
Because panobinostat is still being studied, information on possible side effects of the drug is not complete. As testing of panobinostat continues, additional information on possible side effects will be gathered.
Additional side effects known to be associated with panobinostat are described in the FDA-approved Full Prescribing Information for Farydak.
Where can I get more information about clinical trials studying panobinostat?
More information about panobinostat-related research studies is available from ClinicalTrials.gov.
Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a NIH Clinical Research Trials and You.is right for you. For more information, visit
- United States National Library of Medicine. ChemIDplus Advanced: Panobinostat. https://chem.nlm.nih.gov/chemidplus/rn/404950-80-7. Accessed December 16, 2019.
- Treatment Action Group website. Research toward a cure trials. http://www.treatmentactiongroup.org/cure/trials. Accessed December 16, 2019.
- Novartis Pharmaceuticals Corporation. Farydak: full prescribing information, September 2019. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid = 7774972a-eeaa-4b9a-9e56-3fc1b968e86a. Accessed December 16, 2019.
- Masetti R, Serravalle S, Biagi C, Pession A. The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol. Article ID 148046 2011. doi:10.1155/2011/148046
- Massachusetts General Hospital. A Phase I-II pilot study to assess the safety and efficacy of combined administration with pegylated interferon-alpha2a and the histone deacetylase inhibitor (HDACi) panobinostat for reducing the residual reservoir of HIV-1 infected cells in cART-treated HIV-1 positive individuals. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on June 11, 2015. NLM Identifier: NCT02471430. https://clinicaltrials.gov/ct2/show/NCT02471430. Accessed December 16, 2019.
- University of Aarhus. The safety and efficacy of the histone deacetylase inhibitor panobinostat for purging HIV-1 from the latent reservoir (CLEAR) study. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on September 3, 2012. NLM Identifier: NCT01680094. https://clinicaltrials.gov/ct2/show/NCT01680094. Accessed December 16, 2019.
- Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1(1):a007096.
- Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS. Eliminating the latent HIV reservoir by reactivation strategies. Hum Vaccines Immunother. 2013;9(4):790–799.
- National Institute of Allergy and Infectious Diseases (NIAID). HIV viral eradication. https://www.niaid.nih.gov/diseases-conditions/hiv-viral-eradication. Accessed December 16, 2019.
- Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a Phase 1/2, single group, clinical trial. Lancet HIV. 2014;1(1):e13-21. doi:10.1016/S2352-3018(14)70014-1
Last Reviewed: December 16, 2019